研究单位：[1]Klus Pharma Inc.[2]Los Angeles Hematology Oncology Medical Group,Glendale,California,United States,91204[3]University of California Los Angeles,Los Angeles,California,United States,90404[4]Georgetown University,Washington,District of Columbia,United States,20057[5]Florida Cancer Specialists & Research Institute,Lake Mary,Florida,United States,32746[6]BRCR Medical Center, Inc,Plantation,Florida,United States,33322[7]Florida Cancer Specialists and Research Institute,Sarasota,Florida,United States,34232[8]Willis-Knighton Medical Center,Shreveport,Louisiana,United States,71103[9]Beth Israel Deaconess Medical Center,Boston,Massachusetts,United States,02215[10]START MidWest,Grand Rapids,Michigan,United States,49546[11]The University of Oklahoma Health Sciences Center,Oklahoma City,Oklahoma,United States,73104[12]Oklahoma Cancer Specialists and Research Institute, LLC,Tulsa,Oklahoma,United States,74146[13]Providence Cancer Institute, Franz Clinic,Portland,Oregon,United States,97213[14]Mary Crowley Cancer Research,Dallas,Texas,United States,75230[15]MD Anderson Cancer Center,Houston,Texas,United States,77030[16]Virginia Cancer Specialists,Fairfax,Virginia,United States,22031[17]Princess Margaret Cancer Centre,Toronto,Ontario,Canada[18]Sunnybrook Research Institute,Toronto,Ontario,Canada[19]MUHC,Glen - Women''s Health Research Unit,Montreal,Quebec,Canada[20]The First Affiliated Hospital of Bengbu Medical University,Bengbu,Anhui,China[21]Anhui Cancer Hospital,Hefei,Anhui,China[22]AnHui Provincial Cancer Hospital,Hefei,Anhui,China[23]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China[24]The First Affiliated Hospital of USTC Anhui Provincial Hospital,Hefei,Anhui,China[25]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[26]The Second Hospital of anhui medical University,Hefei,Anhui,China[27]Beijing Cancer Hospital,Beijing,Beijing,China[28]Beijing Cancer Hospital,Beijing,Beijing,China[29]Beijing Chao-Yang Hospital, Capital Medical University,Beijing,Beijing,China[30]Beijing Obstetrics and Gynecology Hospital, Capital Medical University,Beijing,Beijing,China[31]Beijing Tongren Hospital, Capital Medical University,Beijing,Beijing,China[32]Chinese PLA General Hospital (301 Hospital),Beijing,Beijing,China[33]Peking University Third Hospital,Beijing,Beijing,China[34]Chongqing University Cancer Hospital,Chongqing,Chongqing,China[35]Chongqing University Cancer Hospital,Chongqing,Chongqing,China[36]Chongqing University Cancer Hosptital,Chongqing,Chongqing,China[37]900TH Hospital of Joint Logistics Support Force,Fuzhou,Fujian,China[38]Fujian Cancer Hospital,Fuzhou,Fujian,China[39]Fujian Cancer Hospital,Fuzhou,Fujian,China[40]Fujian Cancer Hospital,Fuzhou,Fujian,China[41]Fujian Medical University Uion Hospital,Fuzhou,Fujian,China[42]The First Affiliated Hospital Of Xiamen University,Xiamen,Fujian,China[43]The First Hospital of Lanzhou University,Lanzhou,Gansu,China[44]Affiliated Hospital of Guangdong Medical University,Guangzhou,Guangdong,China[45]Guangdong Provincial People''s Hospital,Guangzhou,Guangdong,China[46]Sun Yat-Sen Memorial Hospital , Sun Yat-sen University,Guangzhou,Guangdong,China[47]Sun Yat-sen Memorial Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China[48]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China[49]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China[50]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China[51]Sun Yat-sen University Cancer prevention Center,Guangzhou,Guangdong,China[52]The Second Affiliated Hospital of Guilin Medical University,Guilin,Guangxi,China[53]Guangxi Medical University Cancer Center,Nanning,Guangxi,China[54]Hainan General Hospital,Haikou,Hainan,China[55]The First Affiliated Hospital of Hainan Medical University,Haikou,Hainan,China[56]The Fourth Hospital of Hebei Medical Univers
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma
